Details of Drug
| Drug General Information (ID: D1486) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name |
Sodium phosphate, monobasic
|
||||||||
| Drug Type | Small molecule | ||||||||
| Drug Synonymous |
2-Methyl-3-(pyridin-4-ylmethyl)quinazolin-4(3H)-one; 7558-80-7; 8871AF; 89140-32-9; Acid sodium phosphate; AKOS024433265; Anhydrous monobasic sodium phosphate; Armite; AT32901; B7779; Buromin; CHEBI:37585; Clicolon; D04400; DB09449; disodium hydrogen phosphate anhydrous; DTXSID7035222; E339; E-339(I); EC 231-449-2; EINECS 231-449-2; EINECS 231-558-5; FT-0698935; Hemisodium phosphate; HSDB 738; HY-Phos; INKP 100; INKP-100; INS NO.339(I); INS-339(I); Instant calgon; KH7I04HPUU; MFCD00003527; MFCD00146206; Monobasic sodium phosphate; Monosodium dihydrogen monophosphate; Monosodium dihydrogen orthophosphate; Monosodium dihydrogen phosphate; Monosodium hydrogen phosphate; Monosodium monophosphate; Monosodium orthophosphate; Monosodium phosphate; Monosodium phosphate anhydrous; Monosodium phosphate, anhydrous; Monosorb XP-4; Na.H2PO4; NaH2PO4; natriumdihydrogen-phosphate; Phosphate, 0.2M buffer solution, pH 4.4; Phosphate, 0.2M buffer solution, pH 6.8; Phosphate, 0.2M buffer solution, pH 7.0; Phosphate, 0.2M buffer solution, pH 7.2; Phosphate, 0.2M buffer solution, pH 7.4; Phosphate, 0.2M buffer solution, pH 7.5; Phosphate, 0.2M buffer solution, pH 7.6; Phosphate, 0.5M buffer solution, pH 6.5; Phosphate, 0.5M buffer solution, pH 7.0; Phosphate, 0.5M buffer solution, pH 7.2; Phosphate, 0.5M buffer solution, pH 7.4; Phosphate, 0.5M buffer solution, pH 8.0; Phosphate, 0.5M buffer solution, pH 8.5; Phosphate, 0.5M buffer solution, pH 9.0; Phosphoric acid, monosodium salt; phosphoric acid, monosodium salt, anhydrous; Phosphoric acid, sodium salt; Phosphoric acid, sodium salt (1:?); Phosphoric acid, sodium salt (1:1); Phosphosoda; Primary sodium phosphate; Q415877; Sodium acid phosphate; Sodium biphosphate anhydrous; Sodium biphosphate, anhydrous; Sodium dihydrogen monophosphate; Sodium dihydrogen orthophosphate; SODIUM DIHYDROGEN PHOSPHATE; Sodium dihydrogen phosphate (1:2:1); Sodium dihydrogen phosphate (NaH2PO4); Sodium dihydrogen phosphate, anhydrous; Sodium dihydrogenorthophosphate; sodium dihydrogenphoshate; sodium dihydrogenphospate; sodium dihydrogenphosphat; sodium dihydrogenphosphate; sodium dihydrogen-phosphate; Sodium dihydrogenphosphate (granular); Sodium monobasic phosphate (NaH2PO4); Sodium orthophosphate monobasic; Sodium orthophosphate, primary; Sodium phosphate (Na(H2PO4)); Sodium phosphate (NaH2PO4); Sodium phosphate glass; Sodium phosphate monobasic; sodium phosphate mono-basic; Sodium phosphate monobasic (anhydrate); Sodium phosphate monobasic (anhydrous); Sodium phosphate monobasic anhydrous; Sodium phosphate monobasic Molecular Biology Grade, suitable for cell culture, insect cell culture, and plant cell culture; Sodium phosphate monobasic solution; Sodium phosphate monobasic solution, BioUltra, 5 M in H2O; Sodium phosphate monobasic, 99.999% trace metals basis; Sodium phosphate monobasic, anhydrous; Sodium phosphate monobasic, anhydrous, free-flowing, Redi-Dri(TM), >=99.0%; Sodium phosphate monobasic, AR, >=98%; Sodium phosphate monobasic, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99.0% (titration); Sodium phosphate monobasic, BioReagent, for molecular biology, anhydrous, >=98%; Sodium phosphate monobasic, Biotechnology Performance Certified, Cell Culture Tested; Sodium phosphate monobasic, BioXtra, >=99.0%; Sodium phosphate monobasic, for HPLC, 99%; Sodium phosphate monobasic, LR, >=97%; Sodium phosphate monobasic, meets USP testing specifications, anhydrous; Sodium phosphate monobasic, purum p.a., anhydrous, >=99.0% (T); Sodium phosphate monobasic, ReagentPlus(R), >=99.0%; Sodium phosphate monobasic, SAJ first grade, 98.0-101.0%; Sodium phosphate monobasic, SAJ special grade, 99.0-101.0%; Sodium phosphate monobasic, USP, 98.0-103.0%; Sodium phosphate monobasic, Vetec(TM) reagent grade, 99%; Sodium phosphate, 0.2M buffer solution, pH 7.0; Sodium phosphate, 0.2M buffer solution, pH 7.2; Sodium phosphate, 0.2M buffer solution, pH 7.4; Sodium phosphate, 0.2M buffer solution, pH 7.5; Sodium phosphate, 0.2M buffer solution, pH 7.6; Sodium phosphate, 0.2M buffer solution, pH 8.0; Sodium phosphate, 0.2M buffer solution, pH 8.5; Sodium phosphate, 0.2M buffer solution, pH 9.0; Sodium phosphate, 0.2M buffer solution, pH 9.5; Sodium phosphate, 0.5M buffer solution, pH 7.0; Sodium phosphate, 0.5M buffer solution, pH 7.5; Sodium phosphate, 0.5M buffer solution, pH 7.6; Sodium phosphate, 0.5M buffer solution, pH 8.0; Sodium phosphate, 0.5M buffer solution, pH 8.5; Sodium phosphate, 0.5M buffer solution, pH 9.0; Sodium phosphate, 0.5M buffer solution, pH 9.5; Sodium phosphate, monobasic (USP); SODIUM PHOSPHATE, MONOBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; Sodium phosphate,monobasic; Sodium primary phosphate; Sodium salt of phosphoric acid; sodium;dihydrogen phosphate; sodiumdihydrogen phosphate; Sodiumdihydrogenphosphate-16O4; Turrixin ST; UNII-3980JIH2SW component AJPJDKMHJJGVTQ-UHFFFAOYSA-M; UNII-KH7I04HPUU; UNII-SE337SVY37 component AJPJDKMHJJGVTQ-UHFFFAOYSA-M
Click to Show/Hide
|
||||||||
| Therapeutic Class | Laxatives/Minerals And Electrolytes | ||||||||
| Drug-Drug Interaction Network | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sunburst Graph |
AM005 Affected excretion pathways
AM006 Pharmacodynamic additive effects
AM007 Pharmacodynamic antagonistic effects
BM029 Altered urine pH
BM063 Increased risk of hypocalcemia
BM107 Attenuated pharmacological effects (Unspecific)
BM109 Increased risk of other adverse reactions (Unspecific)
|
||||||||
| Relation Graph | |||||||||
| Full list of drugs interacting with Sodium phosphate, monobasic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affected excretion pathways | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Altered urine pH | Drug Num: 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Drug ID
|
Drug Name
|
Formula | Pubchem ID | Severity Level | Interaction Detail | REF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0579
|
Ephedrine
|
C10H15NO
|
|
Minor | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0580
|
Ephedrine (nasal)
|
C10H15NO
|
|
Minor | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0664
|
Flecainide
|
C17H20F6N2O3
|
|
Minor | Inter Info |
[9]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D1017
|
Methadone
|
C21H27NO
|
|
Minor | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D1054
|
Mexiletine
|
C11H17NO
|
|
Minor | Inter Info |
[15]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D1363
|
Pseudoephedrine
|
C10H15NO
|
|
Minor | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacodynamic additive effects | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Increased risk of hypocalcemia | Drug Num: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Drug ID
|
Drug Name
|
Formula | Pubchem ID | Severity Level | Interaction Detail | REF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0694
|
Foscarnet
|
CH3O5P
|
|
Moderate | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Increased risk of other adverse reactions (Unspecific) | Drug Num: 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Drug ID
|
Drug Name
|
Formula | Pubchem ID | Severity Level | Interaction Detail | REF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0221
|
Burosumab
|
NA
|
NA
|
Major | Inter Info |
[1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0929
|
Linaclotide
|
C59H79N15O21S6
|
|
Minor | Inter Info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacodynamic antagonistic effects | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Attenuated pharmacological effects (Unspecific) | Drug Num: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Drug ID
|
Drug Name
|
Formula | Pubchem ID | Severity Level | Interaction Detail | REF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
D0590
|
Erdafitinib
|
C25H30N6O2
|
|
Major | Inter Info |
[2]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
